<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36754">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818921</url>
  </required_header>
  <id_info>
    <org_study_id>ZAF-211</org_study_id>
    <nct_id>NCT01818921</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome</brief_title>
  <official_title>Randomized, Double-Blind, Placebo Controlled, Parallel Dose Ranging Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Over-weight and Obese Subjects With Prader-Willi Syndrome to Evaluate Weight Reduction, Food-related Behavior, Safety, and Pharmacokinetics Over 4 Weeks Followed by Optional 4-Week Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zafgen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zafgen, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for
      certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent change in body weight from baseline to the end of the randomized dosing period.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight (kg) from baseline to the end of the randomized dosing period</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hyperphagia behavior, drive, and severity score (total score) from baseline to the end of the randomized dosing period using the PWS Hyperphagia Questionnaire</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Obesity</condition>
  <condition>Over-weight</condition>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>ZGN-440 sterile diluent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.2 mg ZGN-440 for injectable suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.8 mg ZGN-440 for injectable suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZGN-440 sterile diluent</intervention_name>
    <description>ZGN-440 sterile diluent/placebo</description>
    <arm_group_label>ZGN-440 sterile diluent</arm_group_label>
    <other_name>ZGN-440 sterile diluent</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.2 mg ZGN-440 for injectable suspension</intervention_name>
    <description>1.2 mg beloranib</description>
    <arm_group_label>1.2 mg ZGN-440 for injectable suspension</arm_group_label>
    <other_name>ZGN-440 for injectable suspension</other_name>
    <other_name>ZGN-440</other_name>
    <other_name>ZGN-433</other_name>
    <other_name>Beloranib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.8 mg ZGN-440 for injectable suspension</intervention_name>
    <description>1.8 mg beloranib</description>
    <arm_group_label>1.8 mg ZGN-440 for injectable suspension</arm_group_label>
    <other_name>ZGN-440 for injectable suspension</other_name>
    <other_name>ZGN-440</other_name>
    <other_name>ZGN-433</other_name>
    <other_name>Beloranib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Prader-Willi Syndrome due to chromosome 15 micro-deletion,
             maternal uniparental disomy, or imprinting defect

          -  BMI â‰¥25 kg/m2

          -  Type 2 diabetes mellitus is allowed

          -  Subject must agree to stay at the group home or under supervision of the group home
             or site staff (i.e. no home visits) for the duration of the study

          -  Stable body weight during the past 3 months, except for during home visits

        Exclusion Criteria:

          -  Use of weight loss agents in the past 3 months

          -  Type 1 diabetes mellitus

          -  Current or anticipated chronic use of narcotics or opiates
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beloranib</keyword>
  <keyword>ZGN-440</keyword>
  <keyword>ZGN-440 for injectable suspension</keyword>
  <keyword>ZGN-433</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
